MARKET

ATRA

ATRA

Atara Biotherape
NASDAQ
5.39
-0.03
-0.55%
Pre Market: 5.38 -0.01 -0.19% 08:00 03/05 EST
OPEN
5.39
PREV CLOSE
5.42
HIGH
5.50
LOW
5.13
VOLUME
10
TURNOVER
0
52 WEEK HIGH
19.15
52 WEEK LOW
3.920
MARKET CAP
38.86M
P/E (TTM)
2.456
1D
5D
1M
3M
1Y
5Y
1D
Top Atara Biotherapeutics Executives Quietly Cash Out in Latest Insider Moves
TipRanks · 21h ago
Atara, Pierre Fabre seek FDA meeting on EBVALLO
TipRanks · 2d ago
Atara Biotherapeutics' Pierre Fabre Pharmaceuticals Submits Request To FDA For Type A Meeting About ALLELE Trial
Benzinga · 2d ago
Atara Biotherapeutics partner submits Type A meeting request to FDA
TipRanks · 2d ago
Atara Biotherapeutics reports Pierre Fabre request for FDA Type A meeting on tabelecleucel
Reuters · 2d ago
ATARA BIOTHERAPEUTICS PROVIDES REGULATORY UPDATE ON TABELECLEUCEL
Reuters · 2d ago
Weekly Report: what happened at ATRA last week (0223-0227)?
Weekly Report · 3d ago
Atara jumps amid report on FDA’s U-turn on cell therapy
Seeking Alpha · 02/25 18:56
More
About ATRA
Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company. The Company is a developer of T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with serious diseases. Its pipeline products include Ebvallo (Tab-cel), ATA3219, and ATA3431. The Company’s T-cell immunotherapy, tab-cel (tabelecleucel), is in Phase III development for patients with EBV-driven post-transplant lymphoproliferative disease (EBV+ PTLD) who have failed rituximab or rituximab plus chemotherapy, as well as other EBV-driven diseases. Its ATA3219 allogeneic CD19 CAR T immunotherapy, targeting B-cell malignancies and autoimmune diseases, is based on a next-generation 1XX CAR co-stimulatory domain and EBV T-cell platform and does not require TCR or HLA gene editing. ATA3431 is an allogeneic, bispecific CAR directed against CD19 and CD20 for B-cell malignancies and autoimmune disease.

Webull offers Atara Biotherapeutics Inc stock information, including NASDAQ: ATRA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ATRA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ATRA stock methods without spending real money on the virtual paper trading platform.